Crizotinib was initially approved for the treatment of ALK-positive NSCLC and ROS-1-positive NSCLC by the FDA, and it was the first targeted therapy demonstrating a partial response rate in 69 advanced NSCLC patients with METex14 in a phase I PROFILE 1001 study (ORR = 32%, mPFS = 7.3 months) [245]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.